Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.

@article{Hlscher2014CentralEO,
  title={Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.},
  author={Christian H{\"o}lscher},
  journal={The Journal of endocrinology},
  year={2014},
  volume={221 1},
  pages={
          T31-41
        }
}
  • C. Hölscher
  • Published 1 April 2014
  • Biology
  • The Journal of endocrinology
The incretin hormone glucagon-like peptide 1 (GLP-1) has many effects in the body. It is best known for the 'incretin effect', facilitating insulin release from the pancreas under hyperglycaemic conditions. Building on this, GLP-1 mimetics have been developed as a treatment for type 2 diabetes. In the course of monitoring of patients, it has become apparent that GLP-1 mimetics have a range of other physiological effects in the body. In preclinical trials, a substantial body of evidence has been… 

Figures from this paper

GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
TLDR
The biological characteristics of GLP-1 are focused on, an overview of the mechanism of GLp-1 effects in diseases is rendered, and the potential of GL P-1 analogues for the treatment of related diseases are investigated in this review.
Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide.
TLDR
The GLP-1 action through the gut-brain axis, the hormone's regulation of some autonomic functions and liraglutide's neuroprotective potential are discussed.
Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology
TLDR
The beneficial effects on synaptogenesis, neurogenesis, and cell repair as well as the reduction of the chronic inflammatory response, and most importantly the Reduction of amyloid plaques in the brain indicate that these drugs have promise as novel treatments for AD.
The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain
TLDR
Evidence is reviewed related to the role of GLP-1 in type 3 diabetes and how it alleviates learning and memory dysfunction by enhancing the regulation of glucose in the AD brain.
Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases
TLDR
Protease-resistant long-lasting GLP-1 mimetics such as lixisenatide, liraglutide, and exenatide not only have demonstrated promising effects for treating neurodegenerative diseases in preclinical studies but also have shown first positive results in Alzheimer’s disease (AD) and Parkinson's disease (PD) patients in clinical trials.
Oral Galactose Provides a Different Approach to Incretin-Based Therapy of Alzheimer's Disease
TLDR
This review points out another approach to the incretin-related sAD therapy based on the therapeutic potential of oral galactose in a streptozotocin-induced rat model of sporadic AD (STZ-icv model).
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
TLDR
The therapeutic effects and possible mechanisms of action of GLP-1RAs in the nervous, cardiovascular, and endocrine systems and their correlation with metabolism, tumours and other diseases are reviewed.
The Emerging Role of GLP-1 Receptors in DNA Repair: Implications in Neurological Disorders
TLDR
The role of APE1 in neurodegenerative diseases and its relationship to neuroprotective mechanisms of the activated GLp-1 receptor (GLP-1R) in neuro degenerative disorders is reviewed to provide new insight, from the aspect of DNA damage and repair, for studying potential treatments in neuro degenerative diseases.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 147 REFERENCES
Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.
  • C. Holscher
  • Biology, Chemistry
    Recent patents on CNS drug discovery
  • 2010
TLDR
Since two GLP- 1 analogues exendin-4 and liraglutide are already on the market as treatments for Type 2 diabetes, and others are in late stage clinical trials, these drugs show promise as treatment for neurodegenerative diseases such as Alzheimer's disease.
Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease.
TLDR
Its ability to lower brain levels of Abeta in mice would appear to be particularly pertinent in this regard, and the ready availability of clinical material and the clinical history of its long term use in subjects with type 2 diabetes would support testing the value of GLP-1R agonists in AD trials.
GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid.
GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.
TLDR
Ex-4 ameliorated the diabetic effects of STZ in 3xTg-AD mice, elevating plasma insulin and lowering both plasma glucose and hemoglobin A1c (HbA1c) levels and brain levels of Abeta protein precursor and Abeta were significantly reduced in Ex-4 treated mice.
Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
TLDR
The results suggest that these novel incretin analogues cross the blood brain barrier and show physiological activity and neurogenesis in the brain, which may be of use as a treatment of neurodegenerative diseases.
Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
TLDR
It is reported that GLP-1, and its longer-acting analog exendin-4, can completely protect cultured rat hippocampal neurons against glutamate-induced apoptosis and suggest that such peptides may have potential for halting or reversing neurodegenerative processes in CNS disorders, such as Alzheimer's disease, and in neuropathies associated with type 2 diabetes mellitus.
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease
TLDR
The apparent ability of EX-4 to arrest progression of, or even reverse nigral lesions once established, suggests that pharmacological manipulation of the GLP-1 receptor system could have substantial therapeutic utility in PD.
...
1
2
3
4
5
...